Cerecor Inc. (NASDAQ:CERC) is scheduled to be issuing its quarterly earnings data on Monday, November 6th.

Cerecor (NASDAQ:CERC) last released its quarterly earnings results on Monday, August 14th. The company reported ($0.14) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.29) by $0.15. Cerecor had a negative return on equity of 1,325.84% and a negative net margin of 1,106.99%. The business had revenue of $0.16 million during the quarter. On average, analysts expect Cerecor to post $-0.8 EPS for the current fiscal year and $-0.86 EPS for the next fiscal year.

Shares of Cerecor Inc. (CERC) opened at 0.98 on Monday. The firm’s 50-day moving average price is $0.92 and its 200 day moving average price is $0.71. The company’s market cap is $25.53 million. Cerecor Inc. has a 12-month low of $0.34 and a 12-month high of $5.60.

In related news, major shareholder Armistice Capital Master Fund purchased 219,792 shares of the business’s stock in a transaction on Monday, August 21st. The shares were bought at an average cost of $0.60 per share, with a total value of $131,875.20. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders have acquired a total of 1,638,693 shares of company stock worth $1,053,475 over the last ninety days. 10.70% of the stock is owned by insiders.

TRADEMARK VIOLATION NOTICE: “Cerecor Inc. (CERC) to Release Quarterly Earnings on Monday” was originally reported by American Banking News and is the property of of American Banking News. If you are accessing this news story on another domain, it was copied illegally and republished in violation of United States & international copyright legislation. The original version of this news story can be viewed at https://www.americanbankingnews.com/2017/10/30/cerecor-inc-cerc-to-release-quarterly-earnings-on-monday.html.

Cerecor Company Profile

Cerecor, Inc is a clinical stage biopharmaceutical company. The Company is engaged in developing drug candidates for patients with neurological and psychiatric disorders. The Company has a portfolio of clinical and preclinical compounds that it is developing for a range of indications, including CERC-301, which is an adjunctive treatment for major depressive disorder (MDD); CERC-501, which is for substance use disorders and adjunctive treatment of MDD, and CERC-406, which is for the treatment of cognitive impairment.

Earnings History for Cerecor (NASDAQ:CERC)

Receive News & Ratings for Cerecor Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerecor Inc. and related companies with MarketBeat.com's FREE daily email newsletter.